2023: Gyre Therapeutics' net loss increased to $85.5M from $4.3M net income in 2022, while revenues rose to $113.5M.
2023 saw Gyre Therapeutics post a net loss of $85.5M, a reversal from $4.3M net income in 2022. Net loss per share was $1.41 vs a profit of $0.03. Revenues increased to $113.5M, driven by Gyre Pharmaceuticals' indirect controlling interest. Cash and cash equivalents rose to $33.5M from $25.2M in the previous year. (400 characters)
March 26, 2024
3 Articles